Sabra Healthcare REIT, Inc. $SBRA Stock Position Decreased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its holdings in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 0.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,408,114 shares of the real estate investment trust’s stock after selling 31,267 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 1.33% of Sabra Healthcare REIT worth $67,208,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SBRA. Nissay Asset Management Corp Japan raised its holdings in Sabra Healthcare REIT by 1.5% during the 2nd quarter. Nissay Asset Management Corp Japan now owns 38,957 shares of the real estate investment trust’s stock worth $760,000 after buying an additional 585 shares during the period. Versant Capital Management Inc lifted its stake in Sabra Healthcare REIT by 70.0% in the second quarter. Versant Capital Management Inc now owns 1,465 shares of the real estate investment trust’s stock valued at $29,000 after buying an additional 603 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Sabra Healthcare REIT by 7.9% in the third quarter. GAMMA Investing LLC now owns 9,927 shares of the real estate investment trust’s stock valued at $196,000 after buying an additional 724 shares during the period. Anchor Investment Management LLC boosted its holdings in shares of Sabra Healthcare REIT by 17.8% in the second quarter. Anchor Investment Management LLC now owns 4,877 shares of the real estate investment trust’s stock valued at $95,000 after buying an additional 737 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Sabra Healthcare REIT by 21.0% in the first quarter. EverSource Wealth Advisors LLC now owns 4,708 shares of the real estate investment trust’s stock valued at $91,000 after buying an additional 817 shares during the period. 99.40% of the stock is currently owned by institutional investors and hedge funds.

Sabra Healthcare REIT Stock Performance

Shares of SBRA stock opened at $20.35 on Wednesday. Sabra Healthcare REIT, Inc. has a 52 week low of $17.53 and a 52 week high of $22.77. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of 72.68, a PEG ratio of 1.79 and a beta of 0.68. The company has a 50-day simple moving average of $19.85 and a 200 day simple moving average of $19.97. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.07 and a current ratio of 3.07.

Sabra Healthcare REIT (NASDAQ:SBRA) last released its quarterly earnings results on Monday, November 2nd. The real estate investment trust reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.05). Sabra Healthcare REIT had a net margin of 7.78% and a return on equity of 2.56%. The firm had revenue of $249.57 million during the quarter, compared to the consensus estimate of $236.64 million. During the same quarter last year, the firm earned $0.38 earnings per share. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. On average, sell-side analysts predict that Sabra Healthcare REIT, Inc. will post 1.52 earnings per share for the current year.

Sabra Healthcare REIT Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date of this dividend is Friday, November 13th. Sabra Healthcare REIT’s dividend payout ratio (DPR) is currently 461.54%.

Insider Buying and Selling

In other Sabra Healthcare REIT news, CEO Richard Matros sold 200,000 shares of Sabra Healthcare REIT stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $20.83, for a total value of $4,166,000.00. Following the completion of the sale, the chief executive officer owned 1,657,686 shares in the company, valued at $34,529,599.38. The trade was a 10.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.09% of the company’s stock.

Key Stories Impacting Sabra Healthcare REIT

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Sabra raised its 2026 EPS guidance to $1.54–$1.55, above the prior analyst consensus of $1.52. Management also expects 7%–8% year-over-year earnings growth in 2026. Read More.
• Positive Sentiment: Third-quarter revenue rose 31.4% year over year to about $249.6 million, topping the roughly $236.6 million analyst estimate. A report also said quarterly FFO of $0.41 per share beat the $0.40 consensus. Read More.
• Positive Sentiment: Sabra is targeting 50% exposure to its senior housing operating portfolio (SHOP) by the end of 2027. Its CEO pointed to asset optimization and lease negotiations as additional sources of potential upside. Read More. · Read More.
• Positive Sentiment: The REIT declared a quarterly dividend of $0.30 per share, equivalent to $1.20 annually and a reported yield of 6%. Read More.
• Negative Sentiment: Reported third-quarter EPS was $0.11, below the $0.16 consensus and down from $0.38 a year earlier. This earnings shortfall tempers the stronger revenue and outlook news. Read More.

Analysts Set New Price Targets

SBRA has been the topic of a number of research analyst reports. Barclays dropped their price objective on shares of Sabra Healthcare REIT from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. Truist Financial upped their price objective on Sabra Healthcare REIT from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sabra Healthcare REIT in a report on Wednesday, July 22nd. Citigroup reissued a “market outperform” rating on shares of Sabra Healthcare REIT in a research report on Wednesday, July 22nd. Finally, Raymond James Financial raised shares of Sabra Healthcare REIT from an “underperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Sabra Healthcare REIT has a consensus rating of “Moderate Buy” and an average price target of $21.50.

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.